Among the strengths, we were able to leverage an existing database of T2D patients that allowed us to recruit specifically those with rare MT2 mutations, and we collected objective sleep and wake data from actigraphy along with 4 weeks of diet logs. This evidence concerns the gene MTNR1B and type 2 diabetes mellitus.